Forte Biosciences Inc. (FBRX)

Forte Biosciences' stock price increased significantly between March 2025 and March 2026. FBRX shares reached a 52-week high and low. The stock experienced some volatility in late March 2026. Key clinical trial readouts for its FB-102 program are anticipated in 2026. The company reported positive Phase 1b results for FB-102 in celiac disease in June 2025. As of September 30, 2025, Forte Biosciences reported a strong cash and equivalents position. Favorable analyst ratings have contributed to a bullish outlook. Research and development expenses increased significantly in the third quarter of 2025. The company announced inducement grants and presented at investor meetings.

As a clinical-stage biopharmaceutical company, Forte Biosciences, Inc. does not have commercialized products or services in the traditional sense, so there is no typical demand seasonality. The "demand" for the company is primarily related to investor interest, funding, and the progress and outcomes of its clinical trials, which are not subject to seasonal fluctuations.

Forte Biosciences, Inc. (FBRX) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for autoimmune and immune-mediated diseases. Its lead product candidate is FB-102, an anti-CD122 monoclonal antibody therapeutic being advanced through clinical trials for various indications. The company previously had a lead product called FB-401 for inflammatory skin diseases. As a clinical-stage company, Forte Biosciences currently generates no product revenue and funds its operations through capital markets activity.

Forte Biosciences, Inc. is headquartered in Dallas, Texas, United States. The company also has subsidiaries, including Forte Subsidiary, Inc. and Forte Biosciences Australia Pty Ltd, indicating a presence in Australia.

Forte Biosciences' brand reputation appears to be mixed but with a generally positive outlook from analysts. The company has received favorable analyst ratings, but is also classified as a "Distressed" stock type, and has high volatility. One rating agency maintained a "sell" rating on FBRX, citing an unclear regulatory pathway. There were also reports of a large shareholder scolding the company's board of directors and making demands for the company's future.

Forte Biosciences, Inc. has significant institutional ownership. Major institutional owners include Federated Hermes, Inc., Fred Alger Management, LLC, Janus Henderson Group Plc, Orbimed Advisors Llc, Affinity Asset Advisors, LLC, Tybourne Capital Management (hk) Ltd, Vanguard Group Inc, and Point72 Asset Management, L.P. The largest individual shareholder is Steven Michael Oliveira.